Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000954468 | SCV001101103 | likely benign | not provided | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002502960 | SCV002809098 | likely benign | Nephrotic syndrome, type 11; Ovarian dysgenesis 6; Galloway-Mowat syndrome 7 | 2022-04-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002548260 | SCV003754798 | likely benign | Inborn genetic diseases | 2021-10-12 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000954468 | SCV005330151 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | NUP107: BP4, BS1 |
Genome Diagnostics Laboratory, |
RCV000954468 | SCV001930170 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000954468 | SCV001965841 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003978266 | SCV004787767 | likely benign | NUP107-related disorder | 2020-12-15 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |